174 related articles for article (PubMed ID: 19003546)
21. Multiple tumor marker analyses (PSA, hK2, PSCA, trp-p8) in primary prostate cancers using quantitative RT-PCR.
Fuessel S; Sickert D; Meye A; Klenk U; Schmidt U; Schmitz M; Rost AK; Weigle B; Kiessling A; Wirth MP
Int J Oncol; 2003 Jul; 23(1):221-8. PubMed ID: 12792797
[TBL] [Abstract][Full Text] [Related]
22. PTPIP51 mRNA and protein expression in tissue microarrays and promoter methylation of benign prostate hyperplasia and prostate carcinoma.
Koch P; Petri M; Paradowska A; Stenzinger A; Sturm K; Steger K; Wimmer M
Prostate; 2009 Dec; 69(16):1751-62. PubMed ID: 19691131
[TBL] [Abstract][Full Text] [Related]
23. TUG1 promotes the development of prostate cancer by regulating RLIM.
Guo BH; Zhao Q; Li HY
Eur Rev Med Pharmacol Sci; 2019 Mar; 23(5):1926-1933. PubMed ID: 30915735
[TBL] [Abstract][Full Text] [Related]
24. Inhibitor of DNA binding-1 overexpression in prostate cancer: relevance to tumor differentiation.
Yu X; Xu X; Han B; Zhou R
Pathol Oncol Res; 2009 Mar; 15(1):91-6. PubMed ID: 18752043
[TBL] [Abstract][Full Text] [Related]
25. Detection of clinically significant, occult prostate cancer metastases in lymph nodes using a splice variant-specific rt-PCR assay for human glandular kallikrein.
Shariat SF; Kattan MW; Erdamar S; Nguyen C; Scardino PT; Spencer DM; Wheeler TM; Slawin KM
J Clin Oncol; 2003 Apr; 21(7):1223-31. PubMed ID: 12663708
[TBL] [Abstract][Full Text] [Related]
26. Study of PSA, PSMA and hK2 mRNA in peripheral blood of prostate cancer patients and its clinical implications.
Xu T; Chen X; Wang XF; Hou SK; Zhu JC; Zhang XD; Huang XB
Beijing Da Xue Xue Bao Yi Xue Ban; 2004 Apr; 36(2):164-8. PubMed ID: 15100735
[TBL] [Abstract][Full Text] [Related]
27. Prognostic value of combined "triple"-reverse transcription-PCR analysis for prostate-specific antigen, human kallikrein 2, and prostate-specific membrane antigen mRNA in peripheral blood and lymph nodes of prostate cancer patients.
Kurek R; Nunez G; Tselis N; Konrad L; Martin T; Roeddiger S; Aumüller G; Zamboglou N; Lin DW; Tunn UW; Renneberg H
Clin Cancer Res; 2004 Sep; 10(17):5808-14. PubMed ID: 15355910
[TBL] [Abstract][Full Text] [Related]
28. Comparison of human prostate specific glandular kallikrein 2 and prostate specific antigen gene expression in prostate with gene amplification and overexpression of prostate specific glandular kallikrein 2 in tumor tissue.
Herrala AM; Porvari KS; Kyllönen AP; Vihko PT
Cancer; 2001 Dec; 92(12):2975-84. PubMed ID: 11753974
[TBL] [Abstract][Full Text] [Related]
29. Preoperative blood reverse transcriptase-PCR assays for prostate-specific antigen and human glandular kallikrein for prediction of prostate cancer progression after radical prostatectomy.
Shariat SF; Gottenger E; Nguyen C; Song W; Kattan MW; Andenoro J; Wheeler TM; Spencer DM; Slawin KM
Cancer Res; 2002 Oct; 62(20):5974-9. PubMed ID: 12384565
[TBL] [Abstract][Full Text] [Related]
30. [Expression and its significance of b-FGF in human benign prostatic hyperplasia and prostatic carcinoma tissues].
Wang FL; Wang H; Qin WJ; Wu GJ; Zhang G; Li KN
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2004 Mar; 20(2):203-5. PubMed ID: 15191726
[TBL] [Abstract][Full Text] [Related]
31. Total and Gleason grade 4/5 cancer volumes are major contributors of human kallikrein 2, whereas free prostate specific antigen is largely contributed by benign gland volume in serum from patients with prostate cancer or benign prostatic biopsies.
Haese A; Graefen M; Steuber T; Becker C; Noldus J; Erbersdobler A; Huland E; Huland H; Lilja H
J Urol; 2003 Dec; 170(6 Pt 1):2269-73. PubMed ID: 14634394
[TBL] [Abstract][Full Text] [Related]
32. Overexpressed Rce1 is positively correlated with tumor progression and predicts poor prognosis in prostate cancer.
Huang L; Li M; Wang D; He J; Wu W; Zeng Q; Li J; Xiao M; Hu J; He Y; Li Y; Mai L; Liu W
Hum Pathol; 2016 Jan; 47(1):109-14. PubMed ID: 26546252
[TBL] [Abstract][Full Text] [Related]
33. Assessment of optimal target genes for detecting micrometastases in pelvic lymph nodes in patients with prostate cancer undergoing radical prostatectomy by real-time reverse transcriptase-polymerase chain reaction.
Kusuda Y; Miyake H; Kurahashi T; Fujisawa M
Urol Oncol; 2013 Jul; 31(5):615-21. PubMed ID: 21600799
[TBL] [Abstract][Full Text] [Related]
34. Hypermethylation of Cyclin D2 is associated with loss of mRNA expression and tumor development in prostate cancer.
Henrique R; Costa VL; Cerveira N; Carvalho AL; Hoque MO; Ribeiro FR; Oliveira J; Teixeira MR; Sidransky D; Jerónimo C
J Mol Med (Berl); 2006 Nov; 84(11):911-8. PubMed ID: 17016690
[TBL] [Abstract][Full Text] [Related]
35. [Expressions of the androgen receptor in normal prostate, benign prostatic hyperplasia and prostate cancer].
Zeng R; Liu ZY; Sun YH; Xu CL; Gao X; Jiao L
Zhonghua Nan Ke Xue; 2010 Nov; 16(11):967-72. PubMed ID: 21218636
[TBL] [Abstract][Full Text] [Related]
36. Prostate stem cell antigen (PSCA) mRNA expression in peripheral blood in patients with benign prostatic hyperplasia and/or prostate cancer.
Fawzy MS; Mohamed RH; Elfayoumi AR
Med Oncol; 2015 Mar; 32(3):74. PubMed ID: 25698533
[TBL] [Abstract][Full Text] [Related]
37. Comparison of immunohistochemistry with reverse transcription-PCR for the detection of micrometastatic prostate cancer in lymph nodes.
Shariat SF; Roudier MP; Wilcox GE; Kattan MW; Scardino PT; Vessella RL; Erdamar S; Nguyen C; Wheeler TM; Slawin KM
Cancer Res; 2003 Aug; 63(15):4662-70. PubMed ID: 12907647
[TBL] [Abstract][Full Text] [Related]
38. Detection of prostate-specific antigen RNA before and after radical retropubic prostatectomy and transurethral resection of the prostate using "Light-Cycler"-based quantitative real-time polymerase chain reaction.
Straub B; Müller M; Krause H; Schrader M; Goessl C; Heicappell R; Miller K
Urology; 2001 Nov; 58(5):815-20. PubMed ID: 11711374
[TBL] [Abstract][Full Text] [Related]
39. [Clinical significance of expression of PSA, hK2, PSMA in the peripheral blood of patients with prostate cancer].
Cui WG; Zhao H; Song YZ; Zhang J; Zhang LG; Shi JD; Qiang WM
Zhonghua Zhong Liu Za Zhi; 2004 Aug; 26(8):479-81. PubMed ID: 15555338
[TBL] [Abstract][Full Text] [Related]
40. Androgen receptor versus erbB-1 and erbB-2 expression in human prostate neoplasms.
Brys M; Stawinska M; Foksinski M; Barecki A; Zydek C; Miekos E; Krajewska WM
Oncol Rep; 2004 Jan; 11(1):219-24. PubMed ID: 14654929
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
